Zoledronic Acid [For osteoporosis]
💊 Brand Formulations & Prices
7 brands sorted by unit price
Zoledron
Bonizol
Zoldix
Zolenic
Zandra
Zoltero
Aclasta
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesAclasta is indicated in-
Treatment and prevention of postmenopausal osteoporosis
Treatment to increase bone mass in men with osteoporosis
Treatment and prevention of glucocorticoid-induced osteoporosis
Treatment of Paget's disease of bone in men and women
Limitations of Use: Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use.
Hypocalcemia
Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment
Hypersensitivity to any component of Zoledronic Acid
The most common adverse reactions (greater than 10%) were pyrexia, myalgia, headache, arthralgia, pain in extremity. Other important adverse reactions were flu-like illness, nausea, vomiting, diarrhea, and eye inflammation
Hypocalcemia may worsen during treatment. Patients must be adequately supplemented with calcium and vitamin D.
Renal Impairment: A single dose should not exceed 5 mg and the duration of infusion should be no less than 15 minutes. Renal toxicity may be greater in patients with underlying renal impairment or with other risk factors, including advanced age or dehydration. Monitor creatinine clearance before each dose.
Osteonecrosis of the Jaw (ONJ) has been reported. All patients should have a routine oral exam by the prescriber prior to treatment.
Atypical Femur Fractures have been reported. Patients with thigh or groin pain should be evaluated to rule out a femoral fracture.
Severe Bone, Joint, and Muscle Pain may occur. Withhold future doses of Aclasta if severe symptoms occur.
Zoledronic Acid is a bisphosphonate and acts primarily on bone. It is an inhibitor of osteoclast-mediated bone resorption. The selective action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered Zoledronic Acid rapidly partitions to bone and localizes preferentially at sites of high bone turnover. The main molecular target of Zoledronic Acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase. The relatively long duration of action of Zoledronic Acid is attributable to its high binding affinity to bone mineral.